,
Tefferi, A
Al-Ali, H K
Barosi, G
Devos, T
Gisslinger, H
Jiang, Q
Kiladjian, J-J
Mesa, R
Passamonti, F
Ribrag, V
Schiller, G
Vannucchi, A M
Zhou, D
Reiser, D
Zhong, J
Gale, R P
Article History
Received: 10 August 2016
Revised: 2 September 2016
Accepted: 19 September 2016
First Online: 24 October 2016
Competing interests
: HKA-A has received honoraria, research funding and travel expenses from Celgene and Novartis and has acted as a consultant for Novartis; J-JK has acted as a consultant for AOP Orphan and Novartis and received research funding from AOP Orphan; RM has received honoraria from Novartis, received research funding from Celgene, CTI, Gilead and Promedia and acted as a consultant for Ariad and Galena; VR has acted as a consultant for BMS, Gilead, Infinity, Nanostring, PharmaMar and Servier, received honoraria and research funding from ESAI and received travel expenses from Roche; GS has been on a speakers bureau and received research funding from Celgene; AMV has been a member of a board of directors, been on a speakers bureau and received research funding from Novartis; DR and JZ are employed by and own stock or other equity in Celgene Corp.; RPG is a part-time employee of Celgene Corp. and owns stock or other equity of Celgene Corp. RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. The other authors declare no conflict of interest.